Related Experiment Videos
Aryl sulfonamides as selective PDE4 inhibitors
J G Montana1, G M Buckley, N Cooper
1Chiroscience Ltd, Cambridge, UK. johnmontana@chiroscience.com
Bioorganic & Medicinal Chemistry Letters
|January 5, 1999
Summary
Novel phosphodiesterase 4 (PDE4) inhibitors were developed with in vitro and in vivo activity. These selective PDE4 inhibitors show reduced emetic side effects compared to existing treatments.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Drug Discovery
Background:
- Phosphodiesterase 4 (PDE4) is a key enzyme in inflammatory pathways.
- Existing PDE4 inhibitors often cause emetic side effects, limiting their therapeutic use.
- Selective inhibition of PDE4 offers potential therapeutic benefits with reduced side effects.
Purpose of the Study:
- To develop novel selective phosphodiesterase 4 (PDE4) inhibitors.
- To evaluate the in vitro and in vivo activity of these novel compounds.
- To assess the selectivity profile and side effect propensity of the developed inhibitors.
Main Methods:
- Synthesis of novel chemical entities targeting PDE4.
- In vitro enzyme inhibition assays to determine potency and selectivity.
- In vivo studies in animal models to assess efficacy and side effect profiles.
Main Results:
- A series of novel PDE4 inhibitors were successfully synthesized.
- Compounds demonstrated potent in vitro activity against PDE4.
- In vivo studies confirmed efficacy and showed a reduced tendency for emetic side effects.
- Compounds exhibited selectivity for the catalytic site over the Rolipram binding site.
Conclusions:
- Novel selective PDE4 inhibitors with promising therapeutic potential have been developed.
- These compounds offer an improved side effect profile, particularly reduced emesis.
- Further investigation is warranted to explore their clinical applications in inflammatory diseases.